AGIO - アギオス・ファ―マシュ―ティカルズ （Agios Pharmaceuticals Inc.） アギオス・ファ―マシュ―ティカルズAGIOのチャート
AGIOの企業情報
| symbol | AGIO |
|---|---|
| 会社名 | Agios Pharmaceuticals Inc （アギオス・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アジオス・ファーマスーティカルズ(Agios Pharmaceuticals Inc.)はバイオ医薬品会社。同社は根本的に癌と先天性代謝異常(IEM)の治療法を変えるために代謝に対する深い理解と代謝酵素を阻害･活性化できる薬剤を開発する能力を結合して応用しようとする。同社はすでに癌と先天性代謝異常に対して新薬開発の目標を明確･有効にした。同社の2つの進んだ癌プログラムは「IDH1」と「IDH2」と呼ばれるイソクエン酸脱水素酵素1と2の変異を標的とする。同社の薬剤候補は他の細胞に見られるIDH1とIDH2の正常形態に対し、癌に見られるIDH1とIDH2の変異形態を特定する。 アギオス・ファ―マシュ―ティカルズは、がん代謝と先天性代謝異常の分野に特化した米国のバイオ医薬品企業。主製品候補は、変異型イソクエン酸脱水素酵素2｢AG-221｣及びイソクエン酸デヒドロゲナ―ゼ1｢AG-120｣。急性骨髄性白血病などの突然変異IDH2を保有する癌または、突然変異IDH1を保有する癌患者用の強力な阻害剤。 Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across these three therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development. |
| 本社所在地 | 88 Sidney Street Cambridge MA 02139 USA |
| 代表者氏名 | David P. Schenkein David P. Schenkein |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 617-649-8600 |
| 設立年月日 | 39295 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2013年 |
| 従業員数 | 382人 |
| url | www.agios.com |
| nasdaq_url | https://www.nasdaq.com/symbol/agio |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -329.37600 |
| 終値（lastsale） | 68.07 |
| 時価総額（marketcap） | 3947554648.32 |
| 時価総額 | 時価総額（百万ドル） 3819.391 |
| 売上高 | 売上高（百万ドル） 70.33300 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 3102.486 |
| 当期純利益 | 当期純利益（百万ドル） -324.99200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Agios Pharmaceuticals Inc revenues increased from $21.9M to $49.2M. Net loss increased 7% to $159.6M. Revenues reflect Collaboration revenue - related party increase of 54% to $33.7M. Higher net loss reflects Research and development increase of 15% to $146.6M (expense) General and administrative increase of 66% to $38.5M (expense). |
AGIOのテクニカル分析
AGIOのニュース
How did Agios Pharmaceuticals Inc. (AGIO) fare last session? 2023/02/24 15:54:00 US Post News
The share price of Agios Pharmaceuticals Inc. (NASDAQ:AGIO) fell to $26.06 per share on Thursday from $26.52. While Agios Pharmaceuticals Inc. has underperformed by -1.73%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AGIO fell by -9.70%, with highs and lows ranging from $34.76 to $16.75, […]
Agios Pharmaceuticals, Inc. (AGIO) Q4 2022 Earnings Call Transcript 2023/02/23 16:35:35 Seeking Alpha
Agios Pharmaceuticals, Inc. (NASDAQ:NASDAQ:AGIO) Q4 2022 Earnings Conference Call February 23, 2023 8:00 AM ETCompany ParticipantsJessi Rennekamp - Senior Director, Corporate…
Agios Pharmaceuticals GAAP EPS of -$4.23 beats by $2.06, revenue of $14.24M beats by $0.35M (NASDAQ:AGIO) 2023/02/23 12:12:31 Seeking Alpha
Agios Pharmaceuticals press release (AGIO): FY GAAP EPS of -$4.23 beats by $2.06.Revenue of $14.24M beats by $0.35M.$1.1 Billion of Cash, Cash Equivalents and Marketable Securities…
Agios Pharma: Multiple Growth Catalysts If Pyrukynd Conversions Pull Through 2023/02/22 12:10:16 Seeking Alpha
Agios Pharmaceuticals is looking to expand indications for the label into secondary conditions such as sickle cell disease. See why AGIO stock is a Hold now.
Nasdaq - Agios Pharmaceuticals to Release Quarterly Earnings on Thursday 2023/02/16 07:35:15 Business Mag
Agios Pharmaceuticals will release its earnings data before the market opens on Thursday, February 23rd. Analysts expect Agios Pharmaceuticals to post earnings of per share for…
Investing in Agios Pharmaceuticals Inc. (AGIO) might be an excellent idea, but the stock is currently overvalued/undervalued 2023/01/26 16:00:00 US Post News
Agios Pharmaceuticals Inc. (NASDAQ:AGIO) marked $30.78 per share on Wednesday, up from a previous closing price of $29.75. While Agios Pharmaceuticals Inc. has overperformed by 3.46%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AGIO fell by -1.25%, with highs and lows ranging from $34.76 to […]
Agios Pharmaceuticals (AGIO) presents at 41st Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:AGIO) 2023/01/11 18:56:28 Seeking Alpha
The following slide deck was published by Agios Pharmaceuticals, Inc.
Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company''s Vision to Transform Patient Outcomes in Rare Diseases 2023/01/09 01:00:00 Benzinga
– Consistent and compelling clinical data across rare hematological diseases support five ongoing pivotal trials in thalassemia, sickle cell disease and pediatric pyruvate kinase (PK) deficiency – – Driving toward two additional PYRUKYND ® indications, with potential FDA approvals in thalassemia in 2025 and sickle cell disease in 2026 – – Strong cash position expected to enable completion of ongoing programs and pipeline expansion to cash-flow positivity – CAMBRIDGE, Mass., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO ), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced its anticipated 2023 milestones and significant value-driving catalysts through 2026 that support the company''s mission to transform patient outcomes in rare diseases. Agios will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 7:30 a.m. PT, and a live webcast will be available at investor.agios.com . "Agios is poised for significant growth with the potential for approvals in two additional PYRUKYND ® indications by 2026, and is well capitalized to advance its robust existing clinical pipeline and expand its portfolio within our core areas of expertise," said Brian Goff, chief executive officer at Agios. "As the pioneering leader in PK activation with more than seven years of clinical experience with PYRUKYND ® , we have generated an impressive body of consistent and compelling data across rare hematological diseases with shared underlying pathophysiology that further builds confidence in our five ongoing pivotal clinical trials in thalassemia, sickle cell disease and pediatric PK deficiency.
Agios Pharmaceuticals Inc. (NASDAQ: AGIO): Is It Stable And Growing? 2022/12/31 14:00:00 Stocks Register
Agios Pharmaceuticals Inc. (NASDAQ:AGIO) shares, rose in value on Friday, 12/30/22, with the stock price up by 2.41% to the previous day’s close as strong demand from buyers drove the stock to $28.08. Actively observing the price movement in the last trading, the stock closed the session at $27.42, falling within a range of $26.88 … Agios Pharmaceuticals Inc. (NASDAQ: AGIO): Is It Stable And Growing? Read More »
Analysts Predicting A Spike In Agios Pharmaceuticals Inc. (NASDAQ: AGIO)? 2022/12/24 17:00:00 Stocks Register
Agios Pharmaceuticals Inc. (NASDAQ:AGIO) price on Friday, December 23, fall -5.09% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $27.03. A look at the stock’s price movement, the close in the last trading session was $28.48, moving within a range at $26.80 and $28.42. The beta value … Analysts Predicting A Spike In Agios Pharmaceuticals Inc. (NASDAQ: AGIO)? Read More »
The Agios Pharmaceuticals Inc. (AGIO) had a good session last reading, didn’t it? 2022/11/04 14:00:00 US Post News
The share price of Agios Pharmaceuticals Inc. (NASDAQ:AGIO) fell to $26.36 per share on Thursday from $27.82. While Agios Pharmaceuticals Inc. has underperformed by -5.25%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AGIO fell by -46.90%, with highs and lows ranging from $50.98 to $16.75, […]
Agios Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation (NASDAQ:AGIO) 2022/11/04 06:10:29 Seeking Alpha
The following slide deck was published by Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. (AGIO) Q3 2022 Earnings Call Transcript 2022/11/04 06:10:29 Seeking Alpha
Agios Pharmaceuticals, Inc. (NASDAQ:NASDAQ:AGIO) Q3 2022 Earnings Conference Call November 3, 2022 08:00 ET Company Participants Holly Manning - Investor Relations Brian Goff - Chief…
Agios Pharmaceuticals GAAP EPS of -$1.49 beats by $0.27, revenue of $3.52M misses by $1.72M (NASDAQ:AGIO) 2022/11/03 11:23:58 Seeking Alpha
Agios Pharmaceuticals press release (AGIO): Q3 GAAP EPS of -$1.49 beats by $0.27.Revenue of $3.52M misses by $1.72M.Cash, cash equivalents and marketable securities as of September…